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AbstrAct:
We found FAM190A transcripts to have internal rearrangements in 40% (19/48) of 
unselected human cancers. Most of these tumors (84%) had in-frame structures, 
94% of which involved deletion of exon 9. the FAM190A gene is located at 4q22.1 
in a region of common fragility, FrA4F. Although normally stable in somatic cells, 
common fragile sites can be hotspots of rearrangement in cancer. the genomic deletion 
patterns observed at some sites, including FrA4F at 4q22.1, are proposed to be the 
result of selection for disrupted tumor-suppressor genes. Our evidence, however, 
indicated additional patterns for FAM190A. We found genomic deletions accounted 
for some FAM190A in-frame structures, and cases pre-selected for FAM190A 
genomic deletions had a yet higher prevalence of FAM190A rearrangements. Our 
evidence of widespread in-frame heterozygous and homozygous rearrangements 
affecting this gene in tumors of multiple types leads speculation on structural 
grounds that the mutant forms may retain, provide new, or possibly convey 
dominant-negative functions. Although a functionally uncharacterized gene, it is 
evolutionary conserved across vertebrates. In addition to its potential oncogenic role, 
the in-frame deletions predict the formation of cancer-specific FAM190A peptide 
sequences (neo-antigens) with potential diagnostic and therapeutic usefulness.
IntrOductIOn
Common fragile sites (CFS) encompass vast 
chromosomal regions often containing genomically 
large, active genes. Although discovered by applying 
artificial chemical stresses to cell cultures, they can be 
hotspots of natural rearrangement and deletion in cancer 
[1]. Point mutations are rarely found in the coding region 
of genes within CFS [2,3]. Conversely, large intragenic 
homozygous deletions are frequently observed at some 
CFS genes, proposed to be the result of selection for 
disrupted tumor-suppressor genes (TSGs) such as FHIT 
and WWOX [4]. 
The analysis of the CFS DNA sequences has not 
clearly identified the causes of their fragility, but it was 
observed that they share characteristic features such as AT 
base richness, high degrees of DNA flexibility, and late 
DNA replication [5]. Despite their instability, CFSs are 
evolutionary stable regions as proved by their conserved 
features across species [6].
FRA4F is the region of common fragility at 4q22.1. 
Deletion at this locus was reported as a frequent event 
in many tumor types, suggesting 4q22.1 as the site of 
a  not-yet-identified  TSG  [6,7,8,9,10].  A  more  recent 
study of esophageal cancer proposed FAM190A (family 
with  sequence  similarity  190,  member  A;  KIAA1680; Oncotarget 2011; 2:  69 - 75 70 www.impactjournals.com/oncotarget
MGC48628), mapping to 4q22.1, as the TSG [8]. FAM190A 
is a large (1.5 Mb), functionally uncharacterized gene 
with no recognizable protein domain and no sequence 
similarity to other proteins. At least 15 different DNA 
sequence variants are known for FAM190A (http://www.
ncbi.nlm.nih.gov/projects/SNP/,  October  2010)  none  of 
which are associated with disease (http://www.ncbi.nlm.
nih.gov/omim, October 2010).
FAM190A has known transcript variants (http://
insdc.org/,  October  2010),  which  share  100%  identity 
of the 5’ coding sequences to exon 6, but have different 
5’and  3’  UTRs  and  3’  exons.  Variant  1  is  the  longest 
variant,  containing  11  exons  (NM_001145065.1  ); 
variant 2 contains 7 exons (NM_207491.2). Although the 
function of the protein is still unknown, the high degree of 
conservation across vertebrate species suggests that it has 
a conserved, important function. 
In this study we found that the FAM190A 
transcript was very often rearranged in cancer samples. 
A predominance of in-frame deletions speculatively 
suggested a frequent activating mutation such as seen in 
the EGFRvIII rearrangement [11]. We suggest that the 
joined sequences of these in-frame deletions may form 
cancer-specific  peptides  (neo-antigens)  with  potential 
diagnostic and therapeutic relevance.
results
structure of the FAM190A coding sequence
We found partially overlapping homozygous 
genomic deletions (HDs) of 4q22.1 in a pancreatic cancer 
cell line, BxPc3 (reported in ref [9]), and in two of 60 
xenografted pancreatic cancers, PX19 and PX188. A fourth 
homozygous deletion of the same region was reported in a 
lung cancer line, H2126 [12], and a somatic out-of-frame 
deletion of two exons is reported in multiple metastases 
of a single pancreatic cancer [13]. In all five cases, the 
overlapping deleted region included the FAM190A gene.
In order to analyze the transcriptional pattern of 
FAM190A, overlapping primers for the human FAM190A 
transcript variant 1 were designed (see Materials and 
Methods and Table S1). We then performed a PCR-based 
screen of exons 2 to 11 on cDNAs synthesized from 72 
cell lines and xenografted cancer of different types. This 
sample set comprised two panels: 48 unselected samples 
and 24 samples selected for having a known HD or small 
heterozygous  deletions  at  4q22.1  (Table  S2)  [7].  The 
gene was expressed in most samples (92%, 66/72 cases). 
DNA  fragments  of  unexpected  size  were  sequenced. 
In the former panel we found eight types of rearranged 
transcripts  and  internal  rearrangements  in  nearly  40% 
of the cases (39.6%, 19/48 cases). Among these affected 
samples,  84%  had  in-frame  structures,  94%  of  which 
involved deletion of exon 9.
In the latter panel, we found nine types of 
rearrangements and 18 aberrant cases (75%) producing 
exclusively in-frame structures. In 89% of the cases the 
deletion involved exon 9. For each case having a deleted 
FAM190A transcript, we found a co-existing spliced form 
of expected length (wild-type) and/or only a rearranged 
Figure 1. (A) The genomic structure of FAM190A, NM_001145065. Each box represents an exon, numbers above indicate their nucleotide 
lengths. Grey indicates the UTR; white and colors, the exons having nucleotide lengths not divisible and divisible by 3, respectively. (B) A 
magnification of exons from 3 to 11. (C) Top to bottom: structural types of the intragenic deletions, percentage of samples (combined panels) 
affected, percentage of homozygous deletions at the genomic level, type of rearranged transcripts, and predicted aminoacidic sequences at the 
transcript rearrangement joints. *cDNA not examined. **Lack of a PCR product in cDNA from exons 6 to 11. ***Predicted new antigen at the 
joint between normally non-contiguous exons
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DNA
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mRNA alteration                   del 4      del 4-5    del 6       del 7    del 7-8  del 6-7-8-9  del 7-8-9   del 7-8-9-10    del 7,9             del 8      del 8-9    del 8-9-10 del 9   del 9-10     del10
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transcript. Among combined selected and unselected 
cases (Figure 1), the changes appeared homozygous in 24 
samples and heterozygous in 13. Overall, we identified 13 
aberrant structural transcript types between exons 2 and 11: 
11 represented different in-frame deletions (Figures 1 and 
2); the remaining two caused shifting of the reading frame. 
Two cell lines and one xenograft (H1975, SW780, and 
MX7) had multiple rearranged spliced forms. Sequencing 
of the cDNA of AsPc1 revealed no subtle (point) mutation 
in the coding sequence. The sequencing of the cDNA of 
BxPc3  revealed  (beside  the  known  deletion  of  exon  9 
and 10) the presence of a heterozygous nonsynonymous 
SNP at nucleotide 1144 resulting in a missense mutation 
at aminoacid 382. All rearrangements could be replicated 
in a PCR assay using different primers. In one patient, 
four independent parallel xenografts (PX19-1, -2, -3, and 
-4) had been derived from four locations in the resected 
primary tumor. All four had the identical exon deletion, 
indicating  that  the  deletion  had  pre-existed  within  the 
patient’s tumor prior to expansion as xenografts.
At the protein level, the in-frame deletions were 
predicted to form novel peptide sequences (Table 1). 
These are presumptive cancer-specific “neo-antigens”.
The same PCR and sequencing analysis from exon 6 
to exon 11 was conducted on 48 commercially available 
cDNAs from different normal human tissues. Reproducible 
expression of FAM190A transcripts, assessed by multiple 
independent  replicates,  was  found  in  37  samples,  33 
of which had a wild-type FAM190A  transcript  exon 
structure. Four samples had an exon deletion observed 
once: in one case exon 9 was lost; in one exon 8; and in 
two, exon 7. Two samples had a cryptic intronic exon 
inserted, each observed once. Additional samples of the 
organs, however, did not confirm the observed deletion 
or insertion, and these were considered as unconfirmed 
alternative splice variants.
structure of FAM190A transcripts in the 5’ non-
coding region
5’RACE PCR was performed to determine: 1) the 
transcript variants expressed in our samples and 2) the 
structure of the FAM190A transcript in the 5’ non-coding 
region. In a pancreatic cancer cell line, AsPc1, variant 1 
and a novel variant 3 having an alternative first exon were 
observed. Based on this knowledge, RT-PCR conducted 
on a second pancreatic cancer cell line, BxPc3, revealed 
in addition to variant 1, the presence of variant 3 and a 
novel  variant  4  having  an  alternative  first  and  second 
exon. Variant 2 was never observed by us in the samples 
analyzed. In all four variants, the apparent start codon 
ATG is at the position 91229395 (Table 2). 
structure of the genomic FAM190A
In order to rationalize the transcripts through their 
genomic structures, we performed PCR analysis at 
the intron/exon junctions of exons 4 through 10 of 45 
Figure 2: electropherograms showing a wild-type sequence and four of the 13 different rearrangements observed. For each 
cell line the 28bp sequence of the anomalous fusion transcript is depicted. The two boxes on the top of each diagram represent the exon at the 
joint. Colors are as in Figure 1.
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table 1: Variations in the FAM190A coding region transcripts.
Deleted 
exons
 
Consequence
Predicted non-natural peptide 
sequence at the fusion joint*
4-5 Not in frame SSSSKMNSL~ESFPEINKGRX †
6 Not in frame PEFPEPSK~QVQTX
7 In frame LKMKRVLQE~DIMKDECSM
7-8 In frame LKMKRVLQE~GKVRHLQKA‡
7-8-9 In frame LKMKRVLQE~GLNLKRLET
7-8-9-10 In frame LKMKRVLQE~ATYRNRIVS
7 and 9 In frame LKMKRVLQE~DIMKDECSMLKLQL
KEKDELISQLQEEL~GLNLKRLET§,||
8 In frame LTEEPVPFK~GKVRHLQKA
8-9 In frame LTEEPVPFK~GLNLKRLET††
8-9-10 In frame LTEEPVPFK~ATYRNRIVS
9 In frame LISQLQEEL~GLNLKRLET§
9-10 In frame LISQLQEEL~ATYRNRIVS**
10 In frame TQTELLCYD~ATYRNRIVS
before the ~ sign are listed the last nine aminoacidic residues of the exon preceding the deletion. After the ~ sign are listed the 
first nine aminoacidic residues of the exon following the deletion. An underline indicates the aminoacidic residues that would be created due to 
a frame-shift. These two not-in-frame deletions would create a truncated predicted polypeptide. †X, stop codon. For HLA-A*0205, the cognate 
ligand structure – q – g–V– –L matches del7-8‡ and the structure –L– – –L– –L matches the joints produced by del7 and 9§ and del9§. For HLA-A3, 
the ligand structure –V– – – – I–K– matches del7 and 9||, the structure –L– – –L– –Y– matches del9-10**, and the structure – –F– –L– –K– matches 
del8-9†† [26].
    
Variants
 
5’-most exon*
 
Additional 5’ exon       
5’ coding 
exon
start (bp) end (bp) start end start †
#1 91048684 91048982 ----------- ---------- 91229395
    #2‡ 91156182 91156494 ----------- ---------- 91229395
#3 91049688 91049813 ----------- ---------- 91229395
#4 91049688 91049813 91184749 91184873 91229395
table 2: 5’ variations in the FAM190A transcript.
* the genomic positions of the exons are expressed in basepairs according to build Grch37/hg19
† the exon containing the starting codon AtG 
‡ Variant 2 as annotated in the USCS Genome Browser (http://genome.ucsc.edu/), unconfirmed by us. 
Additional unconfirmed 5’ variants are reported in the Ensembl database (http://uswest.ensembl.org/index.html).Oncotarget 2011; 2:  69 - 75 73 www.impactjournals.com/oncotarget
genomic  DNAs  isolated  from  37  cancer  cell  lines  and 
eight pancreatic cancer xenografts. Among these samples, 
23 had rearrangements of their transcripts. In nine, the 
transcript alterations were fully and/or partially explained 
by homozygous losses of genomic material, which 
encompassed only the exons deleted in the corresponding 
transcript. Mechanisms other than genomic deletion might 
underlie the aberrant transcripts in the 14 remaining cases, 
such as undiscovered intronic point mutations, small 
deletions affecting splicing signals, and heterozygous or 
compound heterozygous genomic deletions.
Mouse FAM190A gene (Fam190a)
Four mouse CFSs have been defined at the molecular 
level. Of these, Fra6C1 corresponds to the human FRA4F 
[6]. The murine ortholog of the FAM190A gene, Fam190a, 
maps to mouse chromosome 6 and has two isoforms 
which differ in the 5’UTR but encode the same protein 
(http://www.ncbi.nlm.nih.gov/gene). The human and the 
mouse transcripts share 82% identity of the nucleotide 
coding sequence, suggesting that a deletion pattern similar 
to that observed in the human was possible. To test this 
possibility, we performed a RT-PCR-based screening 
analysis on two murine cancer cell lines (CT38, LLC) and 
one  murine  embryonic  fibroblast  line  (MEF-P3)  along 
with 36 different normal murine tissues. In 27 samples we 
produced an amplified fragment, which was of expected 
size, suggesting that no rearrangements were present. 
We observed widespread expression of Fam190a in both 
newborn and adult murine tissues.
dIscussIOn
The contribution of rare and common fragile 
sites to genome rearrangements and diseases has long 
been studied. Perhaps owing to an unusual nucleotide 
composition and high structural flexibility, fragile sites 
have delayed replication in S phase, a characteristic that 
may lead to the formation of local replicative gaps and 
illegitimate chromosomal rearrangements, and result in 
fixed genomic deletions. 
It is still not clear to what extent these play a role 
in cancer. Recurrent, low-frequency deletions that do 
not retain the reading frame can affect the coding exons 
of the FHIT and WWOX genes at the respective fragile 
sites, and intronic deletions not affecting the structure of 
the mature mRNA also are seen [14,15]. These patterns 
have lead to the controversy whether these genes may be 
either “driver” tumor-suppressor genes or instead reflect 
the uncovering of “passenger” random changes affecting 
fragile sites [16,17,18].
In this study we describe the finding of structural 
defects in the FAM190A  transcript  in  40%  of  human 
cancers and transformed cells. Evidence for widespread 
rearrangements affecting this region in multiple tumor 
types suggests that the mutant coding sequences identified 
might be among the most frequent mutations in human 
cancer. This high frequency is not readily explained by 
the mere coincidental location of FAM190A in a fragile 
region, for the FRA4F site spans about 10 megabasepairs, 
and the affected region evaluated here is less than 5% of 
that span. Nor does FAM190A have a deletion pattern in 
cancers similar to other altered genes evaluated at fragile 
sites, even if we were to restrict our attention to the 
exons (or groups of contiguous exons) contained in these 
genes in which the nucleotide count is a perfect multiple 
of  “3”.  The  remaining  plausible  possibility  is  that  the 
FAM190A changes of cancers is selective, wherein certain 
particular deletions arising from random processes has 
become enriched due to providing a growth advantage 
during neoplastic progression. This selection appears to 
preferentially act upon gross rearrangements, for whole-
exomic and whole-genomic sequencing of human cancers 
(including  ours)  [19]  has  not  found  sub-exonic  subtle 
mutations of this gene such as missense or nonsense 
mutations. 
The deletions of FAM190A might, in theory, be 
recessive or dominant during tumorigenesis. Of the 
rearranged  transcripts,  93%  remained  in-frame  at  the 
fusion (intragenic translocation) joint. Thirteen were 
apparently heterozygous, for a normal transcript co-
existed  with  the  mutant  form.  This  suggests  that  the 
mutant protein products may retain, provide new (or gain 
a) function and they are dominant. Dominant mutant genes 
selected during oncogenesis are classified as oncogenes. 
We found that some of the in-frame rearrangements of 
the transcript had an obvious basis, for they corresponded 
to the exons spanned by intragenic homozygous deletions 
of the genomic DNA. In other instances, a genomic 
basis was implied, for the prevalence rate of FAM190A 
transcript alterations was elevated in cancers pre-selected 
for known heterozygous and homozygous genomic DNA 
deletions in the neighborhood. In the remaining tumors 
having  no  exonic  genomic  deletions,  an  undiscovered 
intronic mutation (similar perhaps to the genomic intronic 
mutations of the CD22 gene in B-precursor leukemia 
proposed as causing exon 12 deletions in the transcripts) 
[20] or an epigenetic mechanism may be the underlying 
cause. 
FAM190A has alternative transcript forms. Transcript 
variants can physiologically be employed to create tissue 
regulatory specificity or protein diversity. In particular, the 
presence of 5’ alternative structures can derive from use 
of alternative promoters and/or from alternative splicing. 
The novel 5’ variants we observed in cancer cells may 
represent a loss of splicing fidelity [21], may subserve a 
tumorigenic role, or may be shared with certain normal 
cells. 
It will be of interest to explore the functional roles 
of FAM190A and how these roles may be altered by the Oncotarget 2011; 2:  69 - 75 74 www.impactjournals.com/oncotarget
intragenic rearrangements. The conservation of the gene 
among  vertebrates,  and  especially  the  sharing  of  exon 
structure and exonic nucleotide lengths between human 
and mouse, suggests that mouse models may be fruitful 
to survey for the normal physiologic roles of FAM190A. 
Additionally, we noted that some of the fusion joints 
match the minimum consensus peptide motives presented 
by the MHC (Table 1). Possibly, the restricted set of fusion 
joints represent neo-antigens that could be clinically typed 
by diagnostic antibody panels, targeted by rearrangement-
specific  therapies,  or  non-invasively  monitored  using 
personalized assays for disease burden [22].
MAterIAl And MethOds
sample collection
72 human tumor specimens, 39 cell lines and 33 
xenografts, were studied. 20 of the cell lines (AsPc1, BT-
20, BT-474, CAPAN1, CAPAN2, CFPAC1, COLO357, 
DLD-1, HeLa, Hs578T, MCF7, MDA-MB-134, MDA-
MB-453, MiaPaCa2, Panc-1, P215, PL45, T470, RKO, 
HEK 293) were randomly chosen from those available to 
us; the other 19 (AGS, BC-1, BxPc3, COLO205, H508, 
H727, HT-1376, H1581, H1975, H2126, H2228, KATO 
III, LNCa-Clone-FGC, LoVo, SW620, SW403, SW780, 
SW837,and SW1417) were selected for a having a known 
deletion affecting 4q22 [7]. The cell lines were obtained 
from European Collection of Cell Cultures (ECACC) 
(COLO357, P215) and American Type Culture Collection 
(ATCC).
33  xenografted  human  cancers  of  different  types 
were obtained from our described tissue banks [23] under 
an IRB-approval protocol. Of these samples, 5 were 
selected  for  a  known  deletion  affecting  4q22  (PX19, 
PX19-2R, PX19-3, PX19-4, PX188) [24] and 28 were 
unselected.
A panel of cDNAs from 48 different human normal 
tissues, was obtained (TissueScan, OriGene).
Three mouse cell lines (CT-38, LLC, MEF-P3) and 
a panel of 36 normal samples representing 18 different 
tissues taken from newborn and adult mice were studied 
by RT-PCR. The organs included heart, stomach, kidney, 
liver, lung, brain cerebellum, brain brainstem, brain 
cortex, pancreas, thymus, spleen, salivary gland, adrenal 
gland, skin, colon and small intestine.
dnA and rnA isolation
Total RNA was extracted from cell lines and tumors 
(Trizol,  Invitrogen).  Purification  was  performed  using 
columns according to manufacturer’s instructions (Rneasy, 
Qiagen). RNA quality was assessed by gel electrophoresis 
of ethidium-bound total RNA. RNA was treated with 
DNase I (Invitrogen) and retrotranscribed (SuperScript® 
III, Invitrogen) to form cDNA. 
Genomic  DNA  was  extracted  according  to 
manufacturer’s instructions (QIAamp, Qiagen). DNA and 
RNA concentrations were determined using spectrometry 
(NanoDrop Technologies).
Primer design, Pcr, and sequence analysis
The primers were designed using Primer3 (http://
frodo.wi.mit.edu/) and synthesized by Integrated DNA 
Technologies (IDT) (Table S3-5). Designed primers were 
aligned against the corresponding genome sequence using 
BLAT  (http://genome.ucsc.edu/cgi-bin/hgBlat, assembly 
Feb  2009,  GRCh37/hg19)  to  confirm  specificity.  Taq 
DNA polymerase was used for the PCR reactions.
PCR conditions were as follows: 94 °C for 4 min, 
72°C for 10 s, and then 40 cycles of 94 °C for 30 s, 55°C 
for 30 s, 72°C for 30 s. PCR products were separated on 
1% agarose gel in lithium boric acid buffer (LB®, Faster 
Better Media LLC) [25] to determine presence and size, 
processed (QIAquick PCR Purification Kit, Qiagen) and 
analyzed by automated sequencing.
rAce Pcr
5’RACE  PCR  was  performed  (FirstChoice  RLM-
RACE, Applied Biosystem) according to manufacturer’s 
instructions.
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